Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

Short summary

Sirolimus, an immunosuppressant, significantly reduced the risk of malignancy by 40% and non-melanoma skin cancer by 56% in kidney transplant recipients compared to controls, with the greatest benefit seen in patients switching to sirolimus. However, it was also associated with a 43% increased risk of death.

AI-generated from the title and abstract; the full text is not read.